Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 44Polycystic Ovary Syndrome 10Breast Diseases 4Advanced Breast Cancer 4Infertility 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Infertility, Female 2is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. 1Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Solid Tumor 1Pathologic Processes 1Obesity 1Myofibroma 1Locally Advanced Breast Cancer 1Hypoxia 1Hydatidiform Mole 1HER2+ Breast Cancer 1Gestational Trophoblastic Disease 1Endometrioid Endometrial Cancer 1Endometrial Neoplasms 1ER Positive, HER2 Negative Breast Cancer 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Cancer Organoids 1Anovulation 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × HER2+ Breast Cancer × Letrozole × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡